A bispecific antibody-drug conjugate (bsADC), BCG033, targeting both TROP2 and PTK7, demonstrated promising preclinical efficacy in triple-negative breast cancer (TNBC) and other solid tumors. The bsADC exhibited high affinity and enhanced internalization in vitro, leading to superior activity compared to benchmark and parental ADCs in TNBC models. Moreover, BCG033 showed potent activity in colorectal cancer models, indicating its potential as a new treatment option for tumors expressing PTK7 and TROP2.